MetaTech Group has integrated its internal resources to obtain global licensing from iPS Academia Japan of Kyoto University. Subsequent commercial development and clinical applications are led by the Group’s subsidiary,Locus Cell Co., Ltd. (6891), establishing MetaTech as an internationally recognized collaborative partner.
The iPSC (induced pluripotent stem cell) technology we actively advance was developed by Professor Shinya Yamanaka, recipient of the 2012 Nobel Prize in Physiology or Medicine. This breakthrough technology enables mature somatic cells to be reprogrammed into stem cells with regenerative potential, fundamentally redefining the long-held belief that cellular differentiation is irreversible. The MetaTech team has successfully transformed human blood cells into beating cardiomyocytes, marking a critical milestone in the transition of iPSC technology from research to clinical application.
In addition to iPSC technology, MetaTech has independently developed Autologous Fibroblast Therapy (M Cell), which has been approved by Taiwan’s Ministry of Health and Welfare under the Regulation Governing the Application of Specific Medical Examination Technique and Medical Device. This proprietary technology has been granted two Taiwan patents and recognized with the 16th National Innovation Award. Applied to skin aging, scar repair, and aesthetic medicine, M Cell combines clinical-grade manufacturing processes with high regenerative activity, demonstrating strong commercial potential.
